MOLCURE
Drug Discovery AI · Drug Discovery
3open roles
4backers · Plug and Play, GMO VenturePartners
10+team · employees, estimated range
19stories in the press
Overview
MOLCURE is an AI company that accelerates drug discovery by combining machine learning, biotechnology and robotics. Its antibody discovery engine relies on NGS analysis pipelines and computational design of candidate sequences, and it hires bioinformatics scientists and AI researchers. The company is based in Tokyo, Japan.
Key facts
As of Nov 13, 2026, Alion lists 3 open roles at MOLCURE. MOLCURE is headquartered in Tokyo, Japan. It was founded in 2019.
- Open roles
- 3Its careers board, read on Nov 13, 2026
- Headquarters
- Tokyo, JapanAlion company profile, updated Nov 12, 2026
- Founded
- 2019Alion company profile, updated Nov 12, 2026
- Employees
- 10+Alion company profile, an estimated range
- Technologies in its job postings
- 13Named in its job postings
Funding and backers
Team
11-50
employees, estimated range
Hiring now
3
+3 posted in 30 days
Backers
4
Plug and Play, GMO VenturePartners
Momentum
55/100
hiring for its size, in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Accelerate drug discovery with physics-based AI. Deep Origin combines simulations and machine learning to predict molecular properties and…
Boltz is a public benefit company building AI-powered molecular modeling tools to make biology programmable and accelerate drug discovery…
Menten AI designs peptide therapeutics using computational protein design combined with quantum and classical optimisation. Founded in 2018…
Superluminal Medicines is a software led drug discovery company focused on helping researchers find and develop new medicines more…
immunitoAI is an AI-driven biotechnology company accelerating antibody discovery and the development of antibody-based therapies through…
From idea to drug molecule in days™. Tell our agent your target and it will handle the rest. The first fully autonomous drug discovery…
Jobs
≈ $19k – $36k per year (Estimated) · In office · Internship · Japan
Machine Learning
Apply
Apply
Apply
Growth
Hiring Momentum
21/100
Hiring freeze
Open positions
3
0 opened / 0 closed in 30 days
Median time-to-fill
206 days
faster than 5% of the market
ATS activity
Every ~6 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
100% ▲
Actively hiring for Early Careers (+3 in 30 days)
Tech stack
Technologies named in job postings at MOLCURE over the last 12 months, by layer, with the share of postings for each.
Technologies in use
13
Postings analysed
3
Stack modernity
92/100AI adopter
Languages
Python
Frameworks & libraries
PyTorch
Cloud & platforms
AWS
GitHub
AI & ML
ChatGPT
Claude
LLM
Sign in to see how your skills match this stack
Sign In
Full MOLCURE tech stack
13 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
STRIVEVia a fund
UTECVia a fund
GMO VenturePartnersVia a fund
Plug and PlayVia a fund
2741 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
BioJapan 2026: MOLCURE to Exhibit and Present, October 7-9
MOLCURE will exhibit at BioJapan 2026, held at PACIFICO Yokohama from Wednesday, October 7, to Friday, October 9, 2026. Visit us at the Cabinet Office Pavilion, Booth A-06. On Thursday, October 8, from 11:00 AM to 12:00 PM JST, CEO/CSO Satoshi Tamaki will
Read more
Report
BioJapan 2026での出展・講演のお知らせ, October 7-9
MOLCUREは、2026年10月7日水から9日金にかけてパシフィコ横浜で開催されるBioJapan 2026に出展します出展ブース：内閣府, ブース番号：A-0610月8日木11:00からブース内ステージで行われるピッチイベントには、当社CEO兼CSOの玉木が登壇します また、10月7日水13:30からは、一般財団法人バイオインダストリー協会JBAが企画するセミナー「新規モダリティAI創薬の現在地と未来」に、当社Chief Innovation Officer (CIO)の小川が登壇します小川は、「AI
Read more
Report
Hitachi Social Innovation Forum 2026 JAPAN Special Seminar Featured MOLCURE, September 4
On Friday, September 4, 2026, our CEO/CSO Satoshi Tamaki spoke at a special seminar hosted by Hitachi, Ltd. Held as part of Hitachi Social Innovation Forum 2026 JAPAN, the seminar was exclusively for the pharmaceutical industry. Related article: "Hitachi
Read more
Report
Hitachi Social Innovation Forum 2026 JAPAN 特別セミナーで講演, September 4
2026年9月4日金、当社CEO兼CSOの玉木が、株式会社日立製作所主催の特別セミナーで講演しました本セミナーは、Hitachi Social Innovation Forum 2026 JAPANの一環として、「抗体医薬とAI創薬が拓く新時代」をテーマに医薬品業界限定で開催されたものです 関連記事：日立、オープンイノベーションによるAI創薬を加速する「秘匿AI基盤」を開発へサービス提供に向けてMOLCUREと協創本格化
Read more
Report
MOLCURE Launches Collaboration with Axcelead Drug Discovery Partners to Discover Peptide Drug Candidates Using MOLCURE's AI-driven Platform, September 8
MOLCURE Inc. ("MOLCURE") today announced that it has entered into an agreement with Axcelead Drug Discovery Partners, Inc. ("Axcelead DDP") to discover peptide drug candidates leveraging MOLCURE's AI-driven platform. Under the project, MOLCURE will apply
Read more
Report
Axcelead Drug Discovery PartnersとAI創薬技術を活用したペプチド創薬で協業を開始, September 8
株式会社MOLCURE本社：神奈川県川崎市、代表取締役CEO兼CSO：玉木 聡志、以下「MOLCURE」は、Axcelead Drug Discovery Partners株式会社本社：神奈川県藤沢市、代表取締役社長：岡田 健吾、以下「Axcelead DDP」と、MOLCUREのAI創薬プラットフォームを活用したペプチド医薬品候補の創製に関する契約を締結しましたのでお知らせいたします 詳細は以下のリンクからプレスリリースをご覧くださいLink: https://prtimes.jp/main/html/
Read more
Report
Innovation Tiger 2026: MOLCURE to Deliver a Finalist Pitch, September 15
On Tuesday, September 15, 2026, from 1:00 PM JST, our CEO/CSO Satoshi Tamaki will take the stage as a finalist at Innovation Tiger 2026, a pitch event hosted by Shonan Health Innovation Park (Shonan iPark). Innovation Tiger is a pitch competition for Asia
Read more
Report
「イノベーションタイガー2026」にMOLCUREがファイナリストとしてピッチ登壇, September 15
2026年9月15日火13:00より、湘南ヘルスイノベーションパーク湘南アイパークが主催するピッチイベント「イノベーションタイガー2026」に、当社CEO兼CSOの玉木がファイナリストとして登壇します 「イノベーションタイガー2026」は、優れたシーズを持ち、将来性のあるアジアの創薬スタートアップおよびアカデミアを対象としたピッチ大会です日本、韓国、台湾から89件の応募があり、MOLCUREがファイナリストに選出されました大手製薬企業および米国系VCが審査員を務めます 今回の登壇を通じて、MOLCUREは
Read more
Report
Speaking at Shonan iPark's 8th VC Consortium Special Event, August 26
On Wednesday, August 26, 2026, from 1:00 PM JST, our CEO/CSO Satoshi Tamaki will speak at the 8th VC Consortium Special Event hosted by Shonan Health Innovation Park (Shonan iPark). The event will bring together business development professionals from pha
Read more
Report
湘南アイパーク「第8回VCコンソーシアムスペシャルイベント」に登壇, August 26
2026年8月26日水13:00より、湘南ヘルスイノベーションパーク湘南アイパークが主催する「創薬/ヘルスケアを加速させる、AI応用商社の基盤新事業を紐解きます 第8回VCコンソーシアムスペシャルイベント」に、当社CEO兼CSOの玉木が登壇します 本イベントでは、製薬企業の事業開発担当者、VC/CVC、スタートアップが集まり、創薬・ヘルスケア領域におけるAIの応用や、商社の事業基盤を活用した新規事業について議論します玉木は、「Session1：生成AIを活用した創薬活動最前線次世代を率いる研究目線の生の声
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Tokyo
Japan
HQ
10-50 est. staff
How to cite this page
Alion, "MOLCURE: key facts", as of Nov 13, 2026. https://alion.io/company/molcure
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0